Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Study of SPI-1005 for Meniere's Disease
NCT06859788Phase 3Active, not recruiting
- Sponsor
- Sound Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ebselen in Meniere's disease (MD), sponsored by Sound Pharmaceuticals. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 360 days. Started Oct 2025; status: active, not recruiting.
02
Drugs
ebselen
03
Conditions
Meniere's disease (MD)
Beyond the preview
Go deeper on NCT06859788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859788.